Your browser doesn't support javascript.
loading
Subclonal TP53 copy number is associated with prognosis in multiple myeloma.
Shah, Vallari; Johnson, David C; Sherborne, Amy L; Ellis, Sidra; Aldridge, Frances M; Howard-Reeves, Julie; Begum, Farzana; Price, Amy; Kendall, Jack; Chiecchio, Laura; Savola, Suvi; Jenner, Matthew W; Drayson, Mark T; Owen, Roger G; Gregory, Walter M; Morgan, Gareth J; Davies, Faith E; Houlston, Richard S; Cook, Gordon; Cairns, David A; Jackson, Graham; Kaiser, Martin F.
Afiliação
  • Shah V; Division of Molecular Pathology, Institute of Cancer Research, London, United Kingdom.
  • Johnson DC; Division of Molecular Pathology, Institute of Cancer Research, London, United Kingdom.
  • Sherborne AL; Division of Molecular Pathology, Institute of Cancer Research, London, United Kingdom.
  • Ellis S; Division of Molecular Pathology, Institute of Cancer Research, London, United Kingdom.
  • Aldridge FM; Centre for Molecular Pathology, The Royal Marsden Hospital, London, United Kingdom.
  • Howard-Reeves J; Centre for Molecular Pathology, The Royal Marsden Hospital, London, United Kingdom.
  • Begum F; Division of Molecular Pathology, Institute of Cancer Research, London, United Kingdom.
  • Price A; Division of Molecular Pathology, Institute of Cancer Research, London, United Kingdom.
  • Kendall J; Division of Molecular Pathology, Institute of Cancer Research, London, United Kingdom.
  • Chiecchio L; Wessex Regional Genetics Laboratory, Salisbury NHS Foundation Trust, Salisbury, United Kingdom.
  • Savola S; MRC-Holland, Amsterdam, Netherlands.
  • Jenner MW; Department of Haematology, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.
  • Drayson MT; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom.
  • Owen RG; Haematological Malignancy Diagnostic Service, St. James's University Hospital, Leeds, United Kingdom.
  • Gregory WM; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, Leeds, United Kingdom.
  • Morgan GJ; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR.
  • Davies FE; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR.
  • Houlston RS; Division of Molecular Pathology, Institute of Cancer Research, London, United Kingdom.
  • Cook G; Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, United Kingdom; and.
  • Cairns DA; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, Leeds, United Kingdom.
  • Jackson G; Department of Haematology, University of Newcastle, Newcastle upon Tyne, United Kingdom.
  • Kaiser MF; Division of Molecular Pathology, Institute of Cancer Research, London, United Kingdom.
Blood ; 132(23): 2465-2469, 2018 12 06.
Article em En | MEDLINE | ID: mdl-30373884
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Proteína Supressora de Tumor p53 / Deleção de Genes / Dosagem de Genes / Instabilidade Genômica / Mieloma Múltiplo Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Revista: Blood Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Proteína Supressora de Tumor p53 / Deleção de Genes / Dosagem de Genes / Instabilidade Genômica / Mieloma Múltiplo Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Revista: Blood Ano de publicação: 2018 Tipo de documento: Article